CAREDX, INC. Proceeds from Sale and Maturity of Marketable Securities
CAREDX, INC. (CDNA) reported Proceeds from Sale and Maturity of Marketable Securities of $54.73 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-04-28
- CAREDX, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $54.73M, a 1.26% decline year-over-year.
- CAREDX, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $28.63M, a 66.99% increase year-over-year.
- CAREDX, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $31.40M, a 15.71% decline year-over-year.
- CAREDX, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-06-30 was $39.21M, a 52.99% increase year-over-year.
- CAREDX, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $154.67M, a 7.34% decline from fiscal 2024.
- CAREDX, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $166.92M, a 34.81% decline from fiscal 2023.
- CAREDX, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $256.04M, a 129.45% increase from fiscal 2022.
- CAREDX, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $111.59M, a 25.51% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-03-31 | $54.73M 10-Q · filed 2026-04-28 | $83.36M derived: sum of 2 quarters · filed 2026-04-28 | $114.76M derived: sum of 3 quarters · filed 2026-04-28 | $153.97M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | $28.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $60.03M derived: sum of 2 quarters · filed 2026-02-25 | $99.24M derived: sum of 3 quarters · filed 2026-02-25 | $154.67M 10-K · filed 2026-02-25 |
| 2025-09-30 | $31.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $70.61M derived: sum of 2 quarters · filed 2025-11-04 | $126.04M 10-Q · filed 2025-11-04 | $143.19M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-06-30 | $39.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $94.64M 10-Q · filed 2025-08-06 | $111.78M derived: sum of 3 quarters · filed 2026-04-28 | $149.04M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-03-31 | $55.43M 10-Q · filed 2026-04-28 | $72.57M derived: sum of 2 quarters · filed 2026-04-28 | $109.83M derived: sum of 3 quarters · filed 2026-04-28 | $135.46M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $17.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $54.40M derived: sum of 2 quarters · filed 2026-02-25 | $80.03M derived: sum of 3 quarters · filed 2026-02-25 | $166.92M 10-K · filed 2026-02-25 |
| 2024-09-30 | $37.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $62.88M derived: sum of 2 quarters · filed 2025-11-04 | $149.78M 10-Q · filed 2025-11-04 | $199.31M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $25.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $112.52M 10-Q · filed 2025-08-06 | $162.06M derived: sum of 3 quarters · filed 2026-02-25 | $222.92M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $86.89M 10-Q · filed 2025-04-30 | $136.43M derived: sum of 2 quarters · filed 2026-02-25 | $197.29M derived: sum of 3 quarters · filed 2026-02-25 | $263.96M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $49.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $110.39M derived: sum of 2 quarters · filed 2026-02-25 | $177.07M derived: sum of 3 quarters · filed 2026-02-25 | $256.04M 10-K · filed 2026-02-25 |
| 2023-09-30 | $60.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $127.53M derived: sum of 2 quarters · filed 2024-11-04 | $206.50M 10-Q · filed 2024-11-04 | $243.96M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $66.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $145.64M 10-Q · filed 2024-07-31 | $183.10M derived: sum of 3 quarters · filed 2025-02-28 | $214.25M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $78.97M 10-Q · filed 2024-05-09 | $116.43M derived: sum of 2 quarters · filed 2025-02-28 | $147.57M derived: sum of 3 quarters · filed 2025-02-28 | $189.51M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $37.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $68.60M derived: sum of 2 quarters · filed 2025-02-28 | $110.53M derived: sum of 3 quarters · filed 2025-02-28 | $111.59M 10-K · filed 2025-02-28 |
| 2022-09-30 | $31.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $73.08M derived: sum of 2 quarters · filed 2023-11-08 | $74.13M 10-Q · filed 2023-11-08 | $84.13M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $41.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $42.98M 10-Q · filed 2023-08-08 | $52.98M derived: sum of 3 quarters · filed 2024-02-28 | $76.81M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.05M 10-Q · filed 2023-05-10 | $11.05M derived: sum of 2 quarters · filed 2024-02-28 | $34.88M derived: sum of 3 quarters · filed 2024-02-28 | $64.89M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $33.83M derived: sum of 2 quarters · filed 2024-02-28 | $63.83M derived: sum of 3 quarters · filed 2024-02-28 | $88.91M 10-K · filed 2024-02-28 |
| 2021-09-30 | $23.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $53.83M derived: sum of 2 quarters · filed 2022-11-03 | $78.91M 10-Q · filed 2022-11-03 | $78.91M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $30.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $55.08M 10-Q · filed 2022-08-04 | $55.08M derived: sum of 3 quarters · filed 2023-02-27 | $55.08M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $25.07M 10-Q · filed 2022-05-05 | $25.07M derived: sum of 2 quarters · filed 2023-02-27 | $25.07M derived: sum of 3 quarters · filed 2023-02-27 | $25.07M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $0.00 derived: sum of 2 quarters · filed 2021-10-28 | $0.00 10-Q · filed 2021-10-28 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $0.00 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |